STANDARD BIOTOOLS INC. - COMMON STOCK

Ascendas Genomics Receives NMPA Approval for Use of Standard BioTools Microfluidics Technology to Advance the Development of Molecular Diagnostics in China

13 Oct 2022 07:30:01 By Nasdaq GlobeNewswire

Standard BioTools Releases the X9 Real-Time PCR System, Its Most Productive and Flexible High-Capacity Genomics Platform

06 Oct 2022 07:30:01 By Nasdaq GlobeNewswire

Standard BioTools Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

25 Aug 2022 15:05:00 By Nasdaq GlobeNewswire

Standard BioTools Announces Second Quarter 2022 Financial Results and Provides Strategic Update

08 Aug 2022 15:02:00 By Nasdaq GlobeNewswire

Standard BioTools Announces Conference Call and Webcast of Second Quarter 2022 Financial Results

25 Jul 2022 15:30:00 By Nasdaq GlobeNewswire

Standard BioTools Announces First Quarter 2022 Financial Results

05 May 2022 15:02:00 By Nasdaq GlobeNewswire

Standard BioTools Announces Conference Call and Webcast of First Quarter 2022 Financial Results

22 Apr 2022 15:02:00 By Nasdaq GlobeNewswire

Standard BioTools Launches Hyperion+ Imaging System, the New Standard in High-Plex Spatial Imaging

11 Apr 2022 07:30:00 By Nasdaq GlobeNewswire

Standard BioTools Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

05 Apr 2022 18:15:24 By Nasdaq GlobeNewswire

Fluidigm Completes $250 Million Strategic Capital Infusion and Changes Name to Standard BioTools Inc.

04 Apr 2022 16:30:57 By Nasdaq GlobeNewswire

Fluidigm Stockholders Approve $250 Million Strategic Capital Infusion

01 Apr 2022 15:05:00 By Nasdaq GlobeNewswire

Fluidigm Announces Support Agreement with Caligan Partners Related to $250 Million Strategic Capital Infusion by Casdin Capital and Viking Global

29 Mar 2022 08:29:06 By Nasdaq GlobeNewswire

Fluidigm Highlights the Strategic Capital Infusion by Casdin Capital and Viking Global as the Only Actionable Financing Solution

28 Mar 2022 07:30:00 By Nasdaq GlobeNewswire

Fluidigm Adjourns Special Meeting of Stockholders Until April 1, 2022

25 Mar 2022 15:00:00 By Nasdaq GlobeNewswire

Fluidigm Urges Stockholders to Vote “FOR” ALL Proposals Related to $250 Million Strategic Capital Infusion TODAY

21 Mar 2022 07:00:01 By Nasdaq GlobeNewswire

Leading Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Fluidigm Stockholders Vote “FOR” ALL Proposals Related to $250 Million Strategic Capital Infusion

17 Mar 2022 16:58:32 By Nasdaq GlobeNewswire

Fluidigm Announces Fourth Quarter and Full Year 2021 Financial Results 

17 Feb 2022 16:43:00 By Nasdaq GlobeNewswire

Fluidigm Announces Collaboration Agreement with the Abu Dhabi Stem Cells Center to Accelerate Imaging Mass Cytometry in Development of Targeted Stem Cell Therapies

17 Feb 2022 07:30:01 By Nasdaq GlobeNewswire

Fluidigm Files Preliminary Proxy Statement in Connection with Proposed Strategic Capital Infusion from Casdin Capital and Viking Global Investors

14 Feb 2022 05:10:00 By Nasdaq GlobeNewswire

Fluidigm Announces $250 Million Strategic Capital Infusion from Casdin Capital and Viking Global Investors and Rebranding to Standard BioTools Inc.

24 Jan 2022 07:30:01 By Nasdaq GlobeNewswire